Maintaining Sexual Function in Later Life

British Longevity Society

London,
February 23, 2009

Dr Michael Perring
mikeperring@optimalhealth.org.uk
Maintaining Sexual Function in Later Life – An Overview

There have been major advances in helping sexual, and particularly erectile, function in men in the past 15 years.

In women advances are less clear: HRT’s benefits are limited; the clinical use of Testosterone is recently licensed while neuro-hormones are being researched.
Maintaining Sexual Function in Later Life – An Overview

PDE5 inhibitors and male and female sex hormones are major aids to the maintenance of sexual function.
Maintaining Sexual Function in Later Life – An Overview

Other factors which may effect continuing sexual activity:

· Psychological health and well-being
· Physical health
· Socio-economic factors.
Maintaining Sexual Function
Social Aspects

What are the findings from large Population Surveys in the past 50 years?
Can we trace the changes in expectations about sex and sexual activity over time?
The Kinsey Report


Pros:
- Ground-breaking
- Fresh insights
- Showed variety of sexual behaviours

Cons:
- Unrepresentative
- Few old, old people

(Cochran et al, 1953)
Men reporting the highest frequency of sexual activity when they were younger had the slowest decline in sexual activity as they got older.

Martin C. Arch Sex Behav 1981;10:399-420
The US Consumer’s Report
Becker 1976

Surveyed population over age 50
Termed them ‘The Silent Generation’
Reported increasing range of sexuality with age
Poor correlation of satisfaction/dysfunction
Sexual activity declined with interest
Importance of intimacy despite absence of SI
The National Council on Aging Report

1988

Report on 1300 Americans over 60:
Sexually Active: 61% of men, 37% of women

- An active sex life important men 79% women 66%
- Men>women wanted more frequent sexual activity 60%
- Sex more emotionally satisfying than aged 40 in 66%
- Qualities sought in a partner: 90% cited high moral character, pleasant personality, humour and intelligence. Men>women cited sex; women>men cited financial security
Social Factors in Maintaining Sexual Function

The most common reason for older people to stop having sex is because they have either divorced or their partner has died.
Frequency of sexual activity:

- Related to availability of a partner
- Inversely related to age
- Inversely related to duration of relationship

i.e., Sixty-year-old in a new relationship may be more sexually active than a 40-year-old in a 15-year relationship.
AARP/Modern Maturity Sexuality Survey 1999

- Quality of interpersonal relationships rated more highly than good sexual relationships
- A generation gap was reported in attitudes to sexuality: the new old will be less accepting of abstinence and dissatisfaction.
A Study of Sexuality and Health among Older adults in the US 2007

- Sexual Activity Declines with Age: 73% of 57-64 year olds, 53% of 65-74 year olds, 26% of 75-85 year olds
- Sexual Activity: Men > women
- 50% M and W had a ‘bothersome’ sexual problem

Cf A US population (all ages) self-identifying as without a sexual problem were in fact found to have a diagnosable sexual difficulty in about 25% of the sample
Amongst the Sexually Active

Women:
- desire 43%,
- vaginal lubrication 39%
- anorgasmia 34%

Men: ED 37%

Medication for erection in 14% of all men surveyed.
Global Study of Sexual Attitudes and Behaviour
Cross-national study of sexual well-being in older men and women
Laumann 2006

Sample of 27,000 aged 40-80 (19% response rate) showed gender and cultural differences:

- Men > women reported sexual well-being;
- Men>women effected by smoking, lack of exercise and biological ageing
- Depression was inversely related to sexual satisfaction
- West Europe, US and Australia higher emotional satisfaction and better sexual relationship cf Mediterranean, Asia and Brazil
- Highest rated importance of sex in Med, Korea, Malaysia, Philippines and Brazil
- Other Asian countries with ‘male-centred’ regimes rated reproduction > sexual satisfaction
Maintaining the Relationship

Sexual intercourse in later life equates with factors other than libido and sexual satisfaction alone.

There is evidence that older women may participate in sexual activity primarily in order to maintain their relationship.

Manderson 2005
Sexual Satisfaction/Disatisfaction in women

Frequency of sexual interest, thoughts and SI correlated with satisfaction in preM and PM women

In sexually dissatisfied women frequency of SI did not correlate with being preM or PM

It is suggested women have SI to maintain their relationship

Manderson 2005
Psychological Factors in Maintaining Sexual Function

Loss of sexual desire in long term relationships:

- ‘Brothers and sisters’
- Separation of interests
- Unresolved issues eg ‘betrayal’
General health
A review of general health is important in maintaining a couple’s sexual function

Hormones and chemical aids to arousal are only part of a complex social/biological system
We should consider:
- Life style factors: nutrition, exercise, ‘stress’
- The relationship: communication skills, intimacy and autonomy
- Cultural and socio-economic factors
Maintaining Sexual Function in Later Life

‘The retention of any human function, be it mental, physical, eg cardiac or sexual, is more likely where that function continues to be exercised.’

PS If having sex is good, it does not follow that having no sex is bad!
Demographics
Life expectancy

For every 24 hours of adult life a further 5 hours of additional life may be added to life expectancy. It will be common place for our children to live into their late 90’s. No ceiling to the increase in life expectancy has been demonstrated.

The 4th Age of Life

In Summary
More of us will live into our 90’s and we can do so leading purposeful lives.
We can relate with intimacy, finding its expression through physical closeness, including sexual activity and with, or without, penetrative sex.
The Maintenance of Sexual Function in later Life

Recommended Reading:

1. Our Bodies, Ourselves by the Boston Women’s Health Collective (Touchstone Books, £36.50). Health-based classic with large section on women’s sexuality.


4. The New Joy of Sex, by Alex Comfort and Susan Quilliam (Octopus Books, £18.99). Re-invented version of the classic thinking person’s guide.

5. Hot Sex by Tracey Cox. For fun, for the young.
The Maintenance of Sexual Function in later Life

Thank you!
Maintaining Sexual Function in Later Life

ECAAAM
Dusseldorf, Germany
September 11-14th, 2008

Dr Michael Perring
mikeperring@optimalhealth.org.uk
Maintaining Sexual Function in Later Life

SEMAL VIIth Anti-Aging Congress
Valencia
October 3-5, 2008

Dr Michael Perring
mikeperring@optimalhealth.org.uk
Maintaining Sexual Function in Later Life – An Overview

There have been major advances in our means to help sexual, and particularly erectile, function in men in the past 15 years.

In women advances are less clear: HRT’s benefits are limited; the clinical use of Testosterone and oxytocin are being researched.

Other factors influence continuing sexual activity (e.g., Psychological, physical health).
Maintaining Sexual Function in Later Life

What are the aids that enable men to maintain better sexual function?

- PDE5 Inhibitors
- Intracavernosal agents
- Non-pharmaceutical aids
Pharmaceutical Aids to Arousal

Sildenafil Citrate (Viagra).

- **Mode of Action**: A phosphodiesterase (PDE5) inhibitor. Its action releases nitric oxide (NO), relaxing endothelial smooth muscle in the corpora cavernosa to fill sinusoidal spaces and give an erection.
- Produces erection with direct stimulation to penis in 60 minutes: duration 12+ hours.
- **Dose**: 25 - 100mg, (75% men respond to 50mg dose)
- **Reduced effectiveness**: anxiety, > libido/desire, and > absorption
Pharmaceutical Aids to Arousal

Sildenafil Citrate (Viagra).

Side-effects:
Due to vaso-congestion are mild and dose-related:
Headaches (16%), GI tract (7%), nasal congestion (4%), and visual disturbances (3%).
CV risk is negligible and sildenafil is compatible with drugs for hypertension. (Chetlin 1999)

Contra-indications: Recent myocardial infarction, concurrent use of nitrates.
Pharmaceutical Aids to Arousal

Sildenafil Citrate (Viagra).

• Reported to have 80% efficacy in organic and psychological forms of ED
  Levine 1996

• In an older population with arteriosclerosis, hypogonadism, drug interactions, hypertension, and radical prostatectomy overall success rate about 50%
  Eidd 2000
Pharmaceutical Aids to Arousal

- Tadalafil (Cialis)
- Mode of action: PDE5 inhibitor.
- Compared to Sildenafil has quicker onset (30 mins).
- ½ life of about 18 hours, and is well-tolerated with similar side-effect profile.
- Efficacy: 80%?
- Dose: 10-20mg
- Contra-indications: CVD (recent MI, unstable angina or angina on SI, arrhythmias and uncontrolled hypertension.)
Pharmaceutical Aids to Arousal

Long term use of PDE5 Inhibitors:

- 60% of men using a PDE5 inhibitor were still using it 2 years later.
- 40% required an increased dose to maintain therapeutic efficacy

El-Galley 2001
Pharmaceutical Aids to Arousal

Alprostadyl (Prostaglandin E1) as injection: Caverject

• **Mode of action**: Relaxes penile vasculature, increasing blood flow into the corpora cavernosa to give an erection.

• Produces erection without direct stimulation to penis within 5 minutes lasting an hour.

• **Dose**: 5-20 micrograms injected into the corpora cavernosa.

• **Side-effects**: Bruising; rarely priapism.
Non-Pharmaceutical Aids to Arousal

• Penile ring: aids erection
  - Erections graded 1-5
  - Ring converts grade 2 erection to grade 3-4
  - Grade 4 erection is good enough for penetration

• Kegel’s exercises: strengthen pelvic floor muscles to aid erection/penetration

• Breathing exercises: aids relaxation

• Sensate Focus training with couple
Erectile Dysfunction (ED)

Definition:
• A persistent inability to attain and maintain an adequate erection to permit satisfactory sexual performance

Prevalence:
In a randomised sample of 1290 men:
• Total ED increased from 5-15% between the ages of 40 and 70.
• Some degree of ED occurred in 52%
• In DM prevalence 15% at 30, < 55% aged 60

MMAS, Feldman 1994
Erectile Dysfunction (ED)

Pathogenesis:

- Physical factors primary cause in 75% of cases. (heart disease, hypertension, DM, and medication)
- Psychological factors predominate in 25% (anger, depression and control issues)
- A psychological reaction of anxiety and avoidant behaviour is a common reaction to established ED
- Life-style factors (stress, cigarette smoking) also correlate with ED

NB Most men over 60 will obtain better erections, quality of orgasm and enhanced sexual experience from the use of PDE5 inhibitors.

Feldman 1994
PDE5 Inhibitors plus Testosterone as the Optimal Aids for Arousal

Where there is erectile difficulty the best treatment is a combination of Testosterone with a PDE5 inhibitor (eg Sildenafil, Vardenafil, Tadalafil) or prostaglandin.

There is still a place for traditional remedies: Yohimbine, Ginseng, Tribulis terrestris, Arginine, etc.
The Androgenic Family

- DHEA, DHEA(S)
- Testosterone
- Dehydrotestosterone (DHT)
- Androstenedione
- Androstenediol
The Androgenic Family
Testosterone

Production:
• Leydig cells produce 5-7mg/ 24 hours,
• ½ life 12 hours
• Dependent on LH
• Release is pulsatile, max between 7-9am, reduced 60% at 5-6.00pm
The Androgenic Family
Testosterone

Transport:
• T not stored in testis
• Bound to SHBG (60-70%), albumen (30%), FT (2-3%)

Clearance:
• Aromatisation at target sites (brain, fat, liver, hair follicles)
• Metabolised by 5 alpha-reductase to DHT (prostate, genitals)
• Conjugation to androsterone, which is water soluble, for excretion.
Androgens and Sexual Function in hypogonadal men

Androgens regulate sexual function with central and peripheral effects:

Centrally:
• < libido (interest and motivation)
  Alexander 1999

Peripherally:
• Activates nitric oxide synthase which regulates activity in cavernosal smooth muscle to promote erection
  Lugg 1996 Shabsigh 2004
Androgens: Other Actions

T has systemic actions other than on sexual function in older men:

• Maintain muscle strength and mass  
  Melton 2000

• Reduce adipose tissue  
  Wittert 2003

• Maintain Bone Density  
  Tenover 1998

• Act on neurones and neuro-transmitters with effects on verbal fluency, memory and energy  
  Alexander 1999

The above benefits to health and QOL, which are unrelated to sexual function directly, none the less benefit it indirectly.
Androgens and Sexual Function in young (and older?) hypogonadal men

T replacement increases

- Sexual activity
- Sexual daydreams, thoughts and desires
- Spontaneous and nocturnal erections

Penile rigidity

1996

Penile sensitivity

Orgasm and ejaculation are androgen dependent

Bhasin 1988

Alexander 1999

Lugg 1996
Partial Androgen Depletion: Andropause/male menopause

- S/S may be variable, gradual in onset, and subtle in clinical presentation. Gooren 1996
- Lean body mass, loss of muscle volume/strength
- Visceral fat
- Bone mineral density (osteopenia/osteoporosis)
- Fatigue, depression and irritability; mental fluency
- Libido and strength of erection (also spontaneous erections and sexual fantasies)
- Body hair and skin tone/thickness. Morales 2000
General Health Evaluation:

Sexual activity is a function of health as a whole, including physical and emotional health.

Prior to assessing for HRT evaluate other pathology.

eg: CVD, DM and Cancer: Testosterone impinges on the progression of these conditions.
Actions of Androgens in Clinical Disease: Ischaemic Heart Disease (IHD)

- T i/v increases coronary artery flow and decreases ischaemic pain (Yue, 1993; Webb, 1999)
- T reduces post-exercise ST segment depression in angina patients (Jaffe, 1977)
- T given for three months to men with chronic stable angina significantly improved tolerance and angina threshold (English, 2000)
Actions of Androgens in Clinical Disease:

Diabetes

- T levels are lower in patients with NIDDM compared to controls. (Stellato, 2000)
- Low total and free T are associated with increased risk of type 2 diabetes. (Stellato, 2000)
- Free T inversely related to glucose and insulin sensitivity. (Haffner, 1996)
- Obesity associated with decreased T; T given to obese men increases insulin sensitivity
Endogenous testosterone and mortality:

In a prospective study of men aged 40-79 low testosterone levels were shown to be associated with a reduced life expectancy and an increased risk cardiovascular disease.

Khaw 2007

From age 45 it is suggested testosterone levels be measured routinely when men present at clinic.
Hormone Therapy: Assessment

Blood tests:

• Hormones: Total testosterone
• Sex Hormone Binding Globulin (SHBG)
• FTI
• Dehydrotestosterone (DHT)
• Dihydroepiandrosterone (DHEA)
• Oestradiol (E2)
• Luteinising Hormone (LH)
• Follicle stimulating Hormone (FSH)
• Prolactin.
Hormone Therapy: Assessment

Other Blood Tests: Full Blood Count (FBC) and Liver Function Tests (LFTs)

- Bone Density: Dexascan
- Assess Prostate Function: ? Family History, current urinary symptoms, DRE, prostate specific antigen (PSA)
- If in doubt do rectal u/s.
HT Assessment:

Some Drugs can interfere with T metabolism:

• Alcohol: Promotes T conversion to E2; damages Leydig cells (↓ sperm production)
• Aminoglutethamide, Ketoconazole: inhibit steroidogenesis and reduce T levels.
• Cimetidine, spironolactone, cyproterone acetate: androgen receptor antagonists
• Saw Palmetto, finasteride: 5-alpha-reductase inhibitors inhibit DHT production (decrease libido and produce ED).
HT Assessment:

Drugs that interfere with SHBG:

- Barbiturates, anticonvulsants: Hepatic enzyme induction increases SHBG reducing urinary clearance of T and FT, and producing symptoms of andropause.

- Danazol lowers hepatic synthesis of SHBG and displaces T from binding sites on SHBG. Produces increased FT levels and counters andropause symptoms.

Curruthers 2000
Treating with Testosterone

- **Orally:** Testosterone undecanoate (Restandol): 80mg twice daily; Natural testosterone 100mg/d
- **Transdermal Patch:** Testosterone (Andropatch) 5mg/d
- **I/m** testosterone as propionate 30mg, phenylpropionate 60mg, isocaproate 60mg, decanoate 100mg (Sustanon): 250mg every two/three weeks
- **I/m** testosterone undecanoate (Nebido) 1000mg every 3 months
- **Cream/gel:** Testosterone (Androgel); DHT (Andractim)
- **Implant:** Testosterone 600mg every 3 months.
Hormone Therapy (HT):

Review of benefits from HT

Meta-analysis of male HT showed testosterone administration is associated with greater improvement in sexual function compared to placebo treatment in men with sexual dysfunction and low testosterone levels.

Jain 2000

Testosterone may also favorably affect partner interactions and intimacy due to an overall increase in sexual desire and sense of well-being, independent of the change in erectile function.

Bhasin 2001
The Oestrogen Family

- derived as a hormonal cascade from cholesterol to pregnenolone, DHEA, progesterone, E2 and testosterone.

Estradiol E2 (7%)  
Derived ovary, strongest action, oral route of admin increases estrone and 16-alpha-hydroxysterone production

Estrone E1 (3%)  
After menopause is derived from adrenal and fat tissue, metabolites are 2-hydroxyestrone, 4-hydroxyestrone and 16-alpha-hydroxyestrone

Low 2:16 ratio relates to Br cancer risk. Phytoestrogens convert 16 to 2-hydroxy estrone

Estriol E3 (90%)  
weakest action, occupying E-receptor sites has moderating action, effective for vaginal dryness

Bradlow 1996, Muti 2000
Oestrogen Depletion

Begins at the perimenopause (35+) and declines rapidly at the menopause (50 years)

Symptoms:
Hot flashes, night sweats, disturbed sleep, fatigue, flatness of affect and anxiety.

Signs:
Physical changes: urinary and vaginal tract atrophy with loss of lubrication and soreness on SI
Cognitive changes: altered memory, concentration, learning capacity
Metabolic effects: altered lipid metabolism
Non systemic HRT management of menopause in women

Symptoms:
• Vaginal and introital dryness, irritation and dysparunia
• Urinary incontinence

Signs
• Atrophy, inflammation
• Poor pelvic muscle tone

Treatment:
• E2 or Estrone as cream, pessary or tablet
• Kegel’s exercises
• Treatment of thrush if necessary
Hormone Therapy (HT) for Women
Risks re-evaluated

After 5 years of combined HT (Oestrogen and progestogen) for every 1000 women their will be:

- **Deep Vein Thrombosis**: 4 extra cases in women over 50
- **Ovarian cancer**: 1 extra case for every 2500 women
- **Strokes**: 1 extra case aged 50-59 years
  - 4 extra cases for women 60+ years
- **Breast cancer**: 2-6 extra cases

Wisdom; Women’s Health Initiative; The Million Women Study, Oxford Uni
Hormone Therapy in Women (HT)

Predictors of HT use:

- Socio-economic status: Higher status associated with greater use.
- Age: Early menopause
- Surgery (hysterectomy) associated with use of HT 3 times more often
Hormone Therapy for Women

In Summary

• We think HT safer than we did – the number of women taking HT remains lower than before the WHI report

• It’s better to start HT early – at the beginning of the menopause for protection against CVD or osteoporosis, as well as for treatment of acute menopausal symptoms such as hot flushes and night sweats

• Some women want to continue HT to age 60+ because of benefits to well-being, libido and sexual function

• They have a choice of replacement therapy with conventional or bio-identical hormones systemically, or topical treatment.
Hormone Therapy for Women

Study: women aged 51-54 years

Adverse effects of HRT less to do with whether women use HRT and more with how it’s applied.

- a cyclic combined regimen with application via the skin is associated with a decreased risk of myocardial infarction by more than one third.

Lokkegaard: *European Heart Journal* September 30, 2008
Hormone Therapy for Women
Androgens

Rationale for Treatment

• Pre-menopausal women produce 300 μg/day of testosterone
  50% from the ovaries
  50% from the adrenal gland
• Post-menopausal women produce about 150 μg/day from the adrenal gland.

Despite treatment with E2 many postmenopausal women continue to have low libido, frequency of SI and sexual satisfaction.
Hormone Therapy for Women
Androgens

- 150-300 μg/day of transdermal testosterone was given to a group of 65 oophorectomised women aged 31-56 years with impaired sexual function.

- The women reported a dose-related increase in sexual thoughts, desires and activities. At the higher dose there was also improvement in mood and well-being.

Shifren 2000
Hormone Therapy (HT):
Androgens for Women

Study: 65 women with impaired sexual function (oophorectomised).

• Age: 31-56
• T/d testosterone (Intrinsa): 300 μg – as patch 2-3 times weekly.

Result:
• Low dose: increase in sexual thoughts, desires and activities.
• High dose: also improvement in mood and well-being

Shifren
Hormone Therapy for Women
Dehydroepiandrosterone (DHEA)

Hormone replacement?

- Normal Range 0.95 - 11.6 mmol/L (women)
  2.20 - 15.2 mmol/L (men)

- Levels are reduced 50% between age 25 and 55
HRT Treatment
Dehydroepiandrosterone (DHEA)

- Replacement doses (DHEA 50mg) were shown to improve energy and well-being in a double-blind cross-over study of a population aged between 40-70 years. Other benefits were reported to sleep and the ability to handle stress

Morales 1994

(This study was with men and women).
DHEA 50mg given for one year to 280 healthy men and women aged 70+ showed (in women only): □ libido, sexual fantasies, activity and satisfaction.

Baulieu1999
Hormone Therapy
Dehydroepiandrosterone (DHEA)

Treatment:
Dose: Oral  50-100mg (men)
       10-25mg (women)
       S/L  25mg (men)
       5-15mg (women)

Side-effects: Changed patterns of hair growth.

NB. Increased levels of testosterone and IGF-1